La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Avanos Medical Gestione
Gestione criteri di controllo 3/4
Avanos Medical's CEO is Joe Woody, appointed in Jun 2017, has a tenure of 7.17 years. total yearly compensation is $7.21M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $5.97M. The average tenure of the management team and the board of directors is 3.9 years and 8.5 years respectively.
Informazioni chiave
Joe Woody
Amministratore delegato
US$7.2m
Compenso totale
Percentuale dello stipendio del CEO | 14.1% |
Mandato del CEO | 7.2yrs |
Proprietà del CEO | 0.6% |
Durata media del management | 3.9yrs |
Durata media del Consiglio di amministrazione | 8.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
There May Be Some Bright Spots In Avanos Medical's (NYSE:AVNS) Earnings
Aug 07Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Apr 17Is Avanos Medical (NYSE:AVNS) A Risky Investment?
Jan 05Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 14When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
Aug 13Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy
Jul 16We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease
Jun 05Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
May 18Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital
May 07Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
Mar 02Avanos Medical Q4 2022 Earnings Preview
Feb 20Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate
Feb 10Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
Jan 13Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance
Nov 02Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Sep 12Avanos Medical Q2 2022 Earnings Preview
Aug 08When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
May 28Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
May 03Is There An Opportunity With Avanos Medical, Inc.'s (NYSE:AVNS) 41% Undervaluation?
Feb 10Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
Dec 21An Intrinsic Calculation For Avanos Medical, Inc. (NYSE:AVNS) Suggests It's 33% Undervalued
Nov 04Avanos Medical (NYSE:AVNS) Takes On Some Risk With Its Use Of Debt
Sep 10The Strong Earnings Posted By Avanos Medical (NYSE:AVNS) Are A Good Indication Of The Strength Of The Business
Aug 10Is There Now An Opportunity In Avanos Medical, Inc. (NYSE:AVNS)?
Jun 30We Think Avanos Medical (NYSE:AVNS) Is Taking Some Risk With Its Debt
Jun 09Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | US$7m |
Mar 31 2024 | n/a | n/a | -US$2m |
Dec 31 2023 | US$7m | US$1m | -US$10m |
Sep 30 2023 | n/a | n/a | -US$11m |
Jun 30 2023 | n/a | n/a | US$9m |
Mar 31 2023 | n/a | n/a | US$18m |
Dec 31 2022 | US$7m | US$1m | US$22m |
Sep 30 2022 | n/a | n/a | US$23m |
Jun 30 2022 | n/a | n/a | -US$23m |
Mar 31 2022 | n/a | n/a | US$10m |
Dec 31 2021 | US$5m | US$960k | -US$31m |
Sep 30 2021 | n/a | n/a | -US$52m |
Jun 30 2021 | n/a | n/a | US$2m |
Mar 31 2021 | n/a | n/a | -US$38m |
Dec 31 2020 | US$8m | US$939k | -US$29m |
Sep 30 2020 | n/a | n/a | US$14m |
Jun 30 2020 | n/a | n/a | -US$17m |
Mar 31 2020 | n/a | n/a | -US$22m |
Dec 31 2019 | US$5m | US$932k | -US$46m |
Sep 30 2019 | n/a | n/a | -US$42m |
Jun 30 2019 | n/a | n/a | -US$27m |
Mar 31 2019 | n/a | n/a | -US$17m |
Dec 31 2018 | US$6m | US$905k | -US$8m |
Sep 30 2018 | n/a | n/a | -US$1m |
Jun 30 2018 | n/a | n/a | -US$16m |
Mar 31 2018 | n/a | n/a | -US$28m |
Dec 31 2017 | US$7m | US$443k | -US$32m |
Compensazione vs Mercato: Joe's total compensation ($USD7.21M) is above average for companies of similar size in the US market ($USD3.30M).
Compensazione vs guadagni: Joe's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Joe Woody (58 yo)
7.2yrs
Mandato
US$7,214,563
Compensazione
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Avanos Medical, Inc. (formerly known as Halyard Health, Inc.) since June 26, 2017. He joined the Avanos Medical, Inc...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO & Director | 7.2yrs | US$7.21m | 0.59% $ 6.0m | |
Senior VP | 4.6yrs | US$2.99m | 0.13% $ 1.3m | |
Senior VP | 3.1yrs | US$1.90m | 0.045% $ 450.6k | |
Senior VP & Chief Commercial Officer | 5.3yrs | US$2.15m | 0.20% $ 2.0m | |
Principal Accounting Officer & Controller | 2.3yrs | Nessun dato | 0.0091% $ 91.3k | |
VP of FP&A and Investor Relations and Treasurer | no data | Nessun dato | Nessun dato | |
Senior VP and Chief Ethics & Compliance Officer | 3.9yrs | Nessun dato | Nessun dato | |
Vice President of Strategy & Corporate Development | no data | Nessun dato | Nessun dato | |
Vice President of Human Resources | no data | Nessun dato | Nessun dato | |
Senior Vice President of Global R&D | no data | Nessun dato | Nessun dato | |
Senior Vice President of Integrated Supply Chain | less than a year | Nessun dato | Nessun dato |
3.9yrs
Durata media
57yo
Età media
Gestione esperta: AVNS's management team is considered experienced (3.9 years average tenure).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO & Director | 7.2yrs | US$7.21m | 0.59% $ 6.0m | |
Independent Director | 9.8yrs | US$292.54k | 0.13% $ 1.3m | |
Independent Chairman | 9.8yrs | US$390.00k | 0.14% $ 1.4m | |
Independent Director | 1.4yrs | US$245.15k | 0.032% $ 322.2k | |
Independent Director | 9.8yrs | US$289.38k | 0.12% $ 1.2m | |
Independent Director | less than a year | Nessun dato | Nessun dato |
8.5yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: AVNS's board of directors are considered experienced (8.5 years average tenure).